{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T02:59:56Z","timestamp":1789441196429,"version":"build-2803163510"},"reference-count":49,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>A substantial implementation gap remains for medications for opioid use disorder (MOUDs), which prevent overdose and associated morbidities. Primary care is an important setting for expanding access opioid use disorder (OUD) treatment.<\/jats:p><\/jats:sec>Objective<\/jats:title>To compare primary care professional (PCP) willingness to treat OUD vs type 2 diabetes in primary care and to assess whether patient race is associated with shaping decisions to treat either condition.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This cross-sectional study used a 2 (chief concern of OUD compared with type 2 diabetes)\u2009\u00d7\u20092 (Black compared with White race) experimental design. Physicians, nurse practitioners, and physician assistants practicing in primary care or a related discipline in Ohio were randomly assigned to each condition and completed assessments between March 1 and June 6, 2024.<\/jats:p><\/jats:sec>Exposure<\/jats:title>Participants received fictitious patient profiles that were identical except that they either described the chief concern as OUD or type 2 diabetes and specified the patient\u2019s race as Black or White.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Clinical and attitudinal outcomes, including willingness to treat the patient in primary care, the amount of time the participant would spend with the patient, and perceptions of the likelihood of disease stabilization, were assessed using 5-point Likert scales (1 = extremely unlikely or strongly disagree, 5 = extremely unlikely or strongly agree). For OUD only, willingness to provide MOUD treatment and harm reduction were assessed.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 375 participants provided complete data (mean [SD] age, 46.8 [13.6] years; 235 female [62.7%]), of whom 191 (50.9%) were physicians (MD or DO), 104 (27.7%) were nurse practitioners, and 80 (21.3%) were physician assistants. Participants viewed type 2 diabetes as more complicated to treat, viewed patients with type 2 diabetes as more responsible for their diagnosis, and had more empathy toward patients with OUD. Participants were significantly more willing to treat type 2 diabetes in primary care (mean [SD], 4.4 [0.1] vs 3.6 [0.1] in the OUD condition) and more likely to refer patients with OUD to a specialist (mean [SD], 4.4 [0.1] vs 3.3 [0.1] in the type 2 diabetes condition). No significant treatment differences were found by patient race. Participants were moderately likely to prescribe an MOUD to the hypothetical patient, with slightly higher willingness to prescribe naltrexone (mean [SD], 3.7 [1.2]) than buprenorphine (mean [SD], 3.4 [1.3]). The most strongly endorsed treatment was referral to an abstinence-based residential treatment organization (mean [SD], 3.9 [1.2]).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>These findings suggest that PCPs have positive attitudes toward treating OUD yet more willingness to treat type 2 diabetes in primary care. Future implementation studies are needed to support MOUD prescribing in primary care.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.34680","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T15:30:34Z","timestamp":1759246234000},"page":"e2534680","source":"Crossref","is-referenced-by-count":1,"title":["Health Care Professional Willingness to Treat Opioid Use Disorder vs Type 2 Diabetes in Primary Care"],"prefix":"10.1001","volume":"8","author":[{"given":"Lindsay Y.","family":"Dhanani","sequence":"first","affiliation":[{"name":"Rutgers University School of Management and Labor Relations, Piscataway, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Brook","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Colorado School of Medicine, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O. Trent","family":"Hall","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Health, The Ohio State University Wexner Medical Center, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Eun","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Public Health Policy and Management, New York University, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berkeley","family":"Franz","sequence":"additional","affiliation":[{"name":"Institute to Advance Health Equity, Ohio University Heritage College of Osteopathic Medicine, Athens"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"issue":"1","key":"zoi250969r1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/jrh.12569","article-title":"Tracking the geographic distribution and growth of clinicians with a DEA waiver to prescribe buprenorphine to treat opioid use disorder.","volume":"38","author":"Andrilla","year":"2022","journal-title":"J Rural Health"},{"issue":"5","key":"zoi250969r2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11920-020-01149-0","article-title":"Identification and management of opioid use disorder in primary care: an update.","volume":"22","author":"Donroe","year":"2020","journal-title":"Curr Psychiatry Rep"},{"key":"zoi250969r3","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2024.104381","article-title":"Buprenorphine dispensing before and after the April 2021 X-waiver exemptions: an interrupted time series analysis.","volume":"126","author":"Roy","year":"2024","journal-title":"Int J Drug Policy"},{"issue":"8","key":"zoi250969r4","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.25999","article-title":"Buprenorphine prescribing characteristics following relaxation of X-waiver training requirements.","volume":"7","author":"Christine","year":"2024","journal-title":"JAMA Netw Open"},{"key":"zoi250969r5","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-024-09260-1","article-title":"The implementation climate for integrating buprenorphine prescribing into rural primary care.","author":"Fenstemaker","journal-title":"J Gen Intern Med"},{"issue":"1","key":"zoi250969r6","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s12954-023-00918-3","article-title":"Differences in buprenorphine prescribing readiness among primary care professionals with and without X-waiver training in the US.","volume":"20","author":"Franz","year":"2023","journal-title":"Harm Reduct J"},{"issue":"4","key":"zoi250969r7","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1080\/08897077.2021.1901172","article-title":"Attitudes toward and experiences working with patients who misuse opioids among board certified physicians in Ohio.","volume":"42","author":"Dhanani","year":"2021","journal-title":"Subst Abus"},{"key":"zoi250969r8","doi-asserted-by":"publisher","DOI":"10.1016\/j.josat.2025.209633","article-title":"Different forms of stigma and rural primary care professionals\u2019 willingness to prescribe buprenorphine.","volume":"171","author":"Franz","year":"2025","journal-title":"J Subst Use Addict Treat"},{"key":"zoi250969r9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ssmmh.2023.100263","article-title":"Positive contact and empathy as predictors of primary care providers\u2019 willingness to prescribe medications for opioid use disorder.","volume":"4","author":"Dhanani","year":"2023","journal-title":"SSM Ment Health"},{"key":"zoi250969r10","doi-asserted-by":"publisher","DOI":"10.1016\/j.abrep.2021.100372","article-title":"Revisiting the relationship between contact and physician attitudes toward patients with opioid use disorder.","volume":"14","author":"Dhanani","year":"2021","journal-title":"Addict Behav Rep"},{"issue":"1","key":"zoi250969r11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13722-021-00242-w","article-title":"Physician blame and vulnerability: novel predictors of physician willingness to work with patients who misuse opioids.","volume":"16","author":"Franz","year":"2021","journal-title":"Addict Sci Clin Pract"},{"issue":"4","key":"zoi250969r12","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.2307\/259164","article-title":"The challenge of innovation implementation.","volume":"21","author":"Klein","year":"1996","journal-title":"Acad Manage Rev"},{"key":"zoi250969r13","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/BF03391707","article-title":"Can substance use disorders be managed using the chronic care model? review and recommendations from a NIDA consensus group.","volume":"35","author":"McLellan","year":"2014","journal-title":"Public Health Rev"},{"issue":"643","key":"zoi250969r14","doi-asserted-by":"publisher","first-page":"e114","DOI":"10.3399\/bjgp16X683509","article-title":"Barriers to effective management of type 2 diabetes in primary care: qualitative systematic review.","volume":"66","author":"Rushforth","year":"2016","journal-title":"Br J Gen Pract"},{"key":"zoi250969r15","doi-asserted-by":"publisher","first-page":"136","DOI":"10.3389\/fpubh.2018.00136","article-title":"From classification to causality: advancing understanding of mechanisms of change in implementation science.","volume":"6","author":"Lewis","year":"2018","journal-title":"Front Public Health"},{"key":"zoi250969r16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.drugalcdep.2016.05.010","article-title":"Primary care physicians\u2019 perspectives on the prescription opioid epidemic.","volume":"165","author":"Kennedy-Hendricks","year":"2016","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"zoi250969r17","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12875-019-1047-z","article-title":"Attitudes of primary care physicians toward prescribing buprenorphine: a narrative review.","volume":"20","author":"Louie","year":"2019","journal-title":"BMC Fam Pract"},{"issue":"10","key":"zoi250969r18","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2022.3856","article-title":"Trends in racial and ethnic disparities in barriers to timely medical care among adults in the US, 1999 to 2018.","volume":"3","author":"Caraballo","year":"2022","journal-title":"JAMA Health Forum"},{"issue":"4","key":"zoi250969r19","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.jemermed.2023.02.015","article-title":"Racial and ethnic differences in emergency department wait times for patients with substance use disorder.","volume":"64","author":"Goldfarb","year":"2023","journal-title":"J Emerg Med"},{"issue":"4","key":"zoi250969r20","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/MLR.0b013e318245a53c","article-title":"Emergency department volume and racial and ethnic differences in waiting times in the United States.","volume":"50","author":"Sonnenfeld","year":"2012","journal-title":"Med Care"},{"issue":"3","key":"zoi250969r21","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2023.0052","article-title":"Association of primary care visit length with potentially inappropriate prescribing.","volume":"4","author":"Neprash","year":"2023","journal-title":"JAMA Health Forum"},{"issue":"9","key":"zoi250969r22","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/jamapsychiatry.2019.0876","article-title":"Buprenorphine treatment divide by race\/ethnicity and payment.","volume":"76","author":"Lagisetty","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"19","key":"zoi250969r23","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMsa2212412","article-title":"Racial inequality in receipt of medications for opioid use disorder.","volume":"388","author":"Barnett","year":"2023","journal-title":"N Engl J Med"},{"key":"zoi250969r24","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1111\/1475-6773.13220","article-title":"Discrimination in the United States: experiences of Black Americans.","volume":"54","author":"Bleich","year":"2019","journal-title":"Health Serv Res"},{"issue":"3-4","key":"zoi250969r25","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1080\/10826080701202627","article-title":"Measuring attitudes toward injecting drug users and people with hepatitis C.","volume":"43","author":"Brener","year":"2008","journal-title":"Subst Use Misuse"},{"issue":"1","key":"zoi250969r26","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1037\/0022-3514.55.1.52","article-title":"Five studies testing two new egoistic alternatives to the empathy-altruism hypothesis.","volume":"55","author":"Batson","year":"1988","journal-title":"J Pers Soc Psychol"},{"issue":"6","key":"zoi250969r27","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1177\/0146167203029006011","article-title":"The antecedents and implications of interracial anxiety.","volume":"29","author":"Plant","year":"2003","journal-title":"Pers Soc Psychol Bull"},{"issue":"1","key":"zoi250969r28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJMp1802741","article-title":"Primary care and the opioid-overdose crisis - buprenorphine myths and realities.","volume":"379","author":"Wakeman","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi250969r29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11606-016-3799-7","article-title":"Barriers to post-acute care for patients on opioid agonist therapy; an example of systematic stigmatization of addiction.","volume":"32","author":"Wakeman","year":"2017","journal-title":"J Gen Intern Med"},{"key":"zoi250969r30","doi-asserted-by":"publisher","DOI":"10.1016\/j.abrep.2024.100541","article-title":"Addressing rural and non-rural substance use disorder stigma: evidence from a national randomized controlled trial.","volume":"19","author":"Ashworth","year":"2024","journal-title":"Addict Behav Rep"},{"issue":"4","key":"zoi250969r31","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1080\/08897077.2019.1640833","article-title":"Underutilization of medications to treat opioid use disorder: what role does stigma play?","volume":"40","author":"Allen","year":"2019","journal-title":"Subst Abus"},{"issue":"1","key":"zoi250969r32","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S2213-8587(23)00347-9","article-title":"Bringing an end to diabetes stigma and discrimination: an international consensus statement on evidence and recommendations.","volume":"12","author":"Speight","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"zoi250969r36","doi-asserted-by":"publisher","first-page":"258","DOI":"10.2337\/dci20-0053","article-title":"Social determinants of health and diabetes: a scientific review.","volume":"44","author":"Hill-Briggs","year":"2020","journal-title":"Diabetes Care"},{"issue":"7","key":"zoi250969r37","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S2213-8587(23)00129-8","article-title":"Disparities in diabetes prevalence and management by race and ethnicity in the USA: defining a path forward.","volume":"11","author":"Hassan","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"zoi250969r39","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s13181-022-00890-7","article-title":"A brief educational intervention to increase ED initiation of buprenorphine for opioid use disorder (OUD).","volume":"18","author":"Khatri","year":"2022","journal-title":"J Med Toxicol"},{"issue":"12","key":"zoi250969r40","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.49103","article-title":"Prescriptions for buprenorphine in Michigan following an education intervention.","volume":"6","author":"Chen","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"1","key":"zoi250969r41","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13722-023-00366-1","article-title":"A randomized controlled trial of an intervention to reduce stigma toward people with opioid use disorder among primary care clinicians.","volume":"18","author":"Hooker","year":"2023","journal-title":"Addict Sci Clin Pract"},{"key":"zoi250969r42","doi-asserted-by":"publisher","DOI":"10.1080\/09687637.2025.2456255","article-title":"Barriers and facilitators to medications for opioid use prescribing in primary care in the United States: a scoping review.","author":"Ukaoma","journal-title":"Drugs Educ Prev Policy"},{"issue":"1","key":"zoi250969r43","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.22605\/RRH3019","article-title":"Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians.","volume":"15","author":"DeFlavio","year":"2015","journal-title":"Rural Remote Health"},{"issue":"11","key":"zoi250969r44","doi-asserted-by":"publisher","first-page":"3996","DOI":"10.1073\/pnas.1320901111","article-title":"Contextual effect of positive intergroup contact on outgroup prejudice.","volume":"111","author":"Christ","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"zoi250969r45","doi-asserted-by":"publisher","first-page":"S199","DOI":"10.1016\/j.amepre.2018.01.004","article-title":"Geographic variation in the supply of selected behavioral health providers.","volume":"54","author":"Andrilla","year":"2018","journal-title":"Am J Prev Med"},{"issue":"1","key":"zoi250969r46","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1370\/afm.1735","article-title":"Geographic and specialty distribution of US physicians trained to treat opioid use disorder.","volume":"13","author":"Rosenblatt","year":"2015","journal-title":"Ann Fam Med"},{"key":"zoi250969r47","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2023.111040","article-title":"Receipt of opioid use disorder treatments prior to fatal overdoses and comparison to no treatment in Connecticut, 2016-17.","volume":"254","author":"Heimer","year":"2024","journal-title":"Drug Alcohol Depend"},{"issue":"8","key":"zoi250969r48","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab289","article-title":"A systematic review and meta-analysis of studies evaluating the effect of medication treatment for opioid use disorder on infectious disease outcomes.","volume":"8","author":"McNamara","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"zoi250969r49","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.amepre.2023.01.037","article-title":"Buprenorphine after nonfatal opioid overdose: reduced mortality risk in Medicare disability beneficiaries.","volume":"65","author":"Samples","year":"2023","journal-title":"Am J Prev Med"},{"key":"zoi250969r33","unstructured":"What is the definition of addiction. American Society of Addiction Medicine. Accessed July 27, 2025. https:\/\/www.asam.org\/quality-care\/definition-of-addiction"},{"key":"zoi250969r34","unstructured":"Kreienkamp? RJ, Voight? BF, Gloyn? AL, Udler? MS. Genetics of type 2 diabetes. In: Lawrence JM, Casagrande SS, Herman WH, et al, eds. Diabetes in America. National Institute of Diabetes and Digestive and Kidney Diseases; 2023. Accessed July 27, 2025. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK597726\/"},{"key":"zoi250969r35","unstructured":"Diabetes risk factors. Centers for Disease Control and Prevention. May 15, 2024. Accessed July 27, 2025. https:\/\/www.cdc.gov\/diabetes\/risk-factors\/index.html"},{"key":"zoi250969r38","unstructured":"The opioid crisis and the Hispanic\/Latino population: an urgent issue. Substance Abuse and Mental Health Services Administration. July 2020. Accessed April 7, 2025. https:\/\/library.samhsa.gov\/product\/opioid-crisis-and-hispaniclatino-population-urgent-issue\/pep20-05-02-002"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2839482\/dhanani_2025_oi_250969_1758638234.29491.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T15:30:36Z","timestamp":1759246236000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2839482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":49,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.34680","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]}}}